Rokote Laboratories Finland Ltd. has secured total of nine million euros of funding for the development of a coronavirus vaccine to be administered as a nasal spray. Ferring Ventures SA, Jenny and Antti Wihuri Foundation, and the Finnish Cultural Foundation have made a capital investment of 3.5 million euros. In addition, Business Finland has granted a 5.5-million-euro loan to the company to support further development and clinical trials of the company\u2019s coronavirus vaccine.<\/p>\n\n\n\n
\u201cThanks to the funding we\u2019ve secured now, we\u2019ll be able to move forward in launching manufacture of the FINCoVac vaccine candidate, and we\u2019ll be able to complete phase I and phase II clinical trials,\u201d Mr\u00a0Pasi Kemppainen\u00a0from Rokote Laboratories Ltd. says.<\/p>\n\n\n\n
The funded coronavirus vaccine is based on research carried out at the University of Helsinki and the University of Eastern Finland, namely in the laboratories of Professor of Virology\u00a0Kalle Saksela, Academician\u00a0Kari Alitalo, and Academy Professor\u00a0Seppo Yl\u00e4-Herttuala. This research has been supported by the Academy of Finland, the Wihuri Research Institute, and the Sakari Alhopuro Foundation. Both universities are also shareholders in the company.\u00a0\u00a0<\/p>\n\n\n\n
The vaccine is based on gene transfer technology developed by Yl\u00e4-Herttuala\u2019s research group, and the technology has already been successfully used in several clinical trials using gene therapy to treat cardiovascular diseases and cancer.<\/p>\n\n\n\n
\u201cThe vaccine uses a safe adenovirus carrier that contains a cloned DNA strand of the SARS-Cov-2 virus\u2019s S protein. This can be used to program nasopharyngeal cells to produce the surface protein of the SARS-CoV-2 virus which, in turn, produces a response to the vaccine. There are no other parts of the virus in the vaccine,\u201d Yl\u00e4-Herttuala says.<\/p>\n\n\n\n
The genome of the SARS-CoV-2 virus is expected to continue mutating rapidly.<\/p>\n\n\n\n
\u201cWith the vaccine we are developing now, we seek to tackle the challenge posed by new virus mutations. In the future, the vaccine can serve as an easy-to-administer booster for those who have already received a traditional vaccine,\u201d Saksela says.<\/p>\n\n\n\n
Later on, the same method can also be used to develop vaccines against other viruses.<\/p>\n\n\n\n
\u201cThe work carried out by Rokote Laboratories Finland Ltd. will make the use of a novel vaccine technology established here in Finland. This technology will also make us better prepared for possible future pandemics,\u201d Saksela points out.<\/p>\n\n\n\n
<\/p>\n","protected":false},"author":1760,"featured_media":235371,"template":"","meta":{"_acf_changed":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":""},"categories":[34665],"tags":[48731,48127,54711,48874],"location":[],"internal_archives":[],"class_list":["post-298574","selected","type-selected","status-publish","has-post-thumbnail","hentry","category-health","tag-corona-en","tag-covid-19","tag-nasal-spray","tag-vaccine"],"blocksy_meta":[],"acf":[],"featured_img":false,"coauthors":[],"author_meta":{"author_link":"https:\/\/ioplus.nl\/archive\/author\/arnoud-cornelissen\/","display_name":"Arnoud Cornelissen"},"relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on July 7, 2021","modified":"Updated on July 7, 2021"},"absolute_dates_time":{"created":"Posted on July 7, 2021 1:00 pm","modified":"Updated on July 7, 2021 1:00 pm"},"featured_img_caption":"","tax_additional":{"category":{"linked":["Health<\/a>"],"unlinked":["Health<\/span>"],"slug":"category","name":"Categories"},"post_tag":{"linked":["Corona<\/a>","COVID-19<\/a>","nasal spray<\/a>","vaccine<\/a>"],"unlinked":["Corona<\/span>","COVID-19<\/span>","nasal spray<\/span>","vaccine<\/span>"],"slug":"post_tag","name":"Tags"},"language":{"linked":["EN<\/a>"],"unlinked":["EN<\/span>"],"slug":"language","name":"Tags"},"post_translations":{"linked":["pll_60e5644a5b52a<\/a>"],"unlinked":["pll_60e5644a5b52a<\/span>"],"slug":"post_translations","name":""},"location":{"linked":[],"unlinked":[],"slug":"location","name":"Locations"},"internal_archives":{"linked":[],"unlinked":[],"slug":"internal_archives","name":"Internal Archives"}},"series_order":"","_links":{"self":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/selected\/298574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/selected"}],"about":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/types\/selected"}],"author":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/users\/1760"}],"wp:attachment":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media?parent=298574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/categories?post=298574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/tags?post=298574"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/location?post=298574"},{"taxonomy":"internal_archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/internal_archives?post=298574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}